Log In Request a Trial

Special Report

Anticompetitive Practices in the Pharma Supply Chain

The report includes in-depth analysis on our findings of Teva’s Copaxone and Biogen’s Tecfidera, including price and market share data compared to the generic formularies, plan analysis of drugs covered, and more.

Download

Discover the Benefits of a Subscription

Our content provides subscribers with unique insight and breaking news regarding the most complex mergers and regulatory situations around the world.

Inquire

The Capitol Forum Advantage

Our work combines cutting edge breaking news with in-depth analysis to better inform readers how policy and regulation affects market competition.

Learn More

The Capitol Forum Community

Our editorial team reconstructs the policy process to yield market insight for a community of subscribers including government regulators, lawyers, investors, and non-profits.

Learn More

FEATURED ARTICLES

View all

Zynex: Company’s Accounting Practices Raise Red Flags, According to Accounting Experts

The accounting practices of Zynex (ZYXI), a manufacturer of electrotherapy...

May 24, 2023

Congressional Committee, Regulators Question Cigna System that Lets Its Doctors Deny Claims without Reading Patient Files

This article is published in partnership with ProPublica. A key congressional...

May 16, 2023

Amgen/Horizon: FTC Prepares to Sue to Block $27.8 Billion Pharmaceutical Transaction

The FTC is preparing to sue to block Amgen’s (AMGN) proposed $27.8 billion...

May 15, 2023

RECENT PODCASTS

View all

Philip Mattera on Pay for Delay

Listen

This week on Second Request, the Hatch-Waxman Act of 1984 laid out a pathway...

Jun 01, 2023

Structural Presumption for Merger Review with Tommaso Valletti

Listen

Tommaso Valletti is Professor of Economics at Imperial College Business School...

May 25, 2023

ABOUT THE CAPITOL FORUM

We are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy issues.

COVERAGE

TESTIMONIALS

Karl A. Racine - Former D.C. Attorney General

“I appreciate the helpful work done by The Capitol Forum. It’s one of the sources I turn to for information about what activity is out there not only in the antitrust space, but also in the consumer protection world.”

Melissa H. Maxman - Partner, Cohen & Gresser

“I have become an avid reader of The Capitol Forum because it provides timely in-depth news and analysis of the myriad legal, business, legislative and political factors affecting business developments. I always come away with fresh perspectives that help me advise my clients about current issues.”

Professor Thomas J. Horton - The University of South Dakota School of Law

“I eagerly read every report from The Capitol Forum and have great admiration for its reporters and editors. I find it to be the single best source of up-to-the-minute coverage and objective in-depth analysis of cutting-edge antitrust news and other critical competition-related developments.”

Barry Nigro - Partner and Antitrust Chair, Fried Frank

“The Capitol Forum’s news and analysis is spot on and reflects a perfect mix of investigative reporting, independent research, and expert opinion.”

Bert Foer - Former President, American Antitrust Institute

“The Capitol Forum provides an always interesting and sometimes surprising look under the hood about pending antitrust activities.”

Barry Lynnn - Citizens Against Monopoly

“The Capitol Forum is the only team covering this incredibly important beat. Better yet, their work is deeply intelligent, influential, and almost always right.”

Allen Grunes - Co-Founder, Konkurrenz Group

“The Capitol Forum consistently provides timely and sophisticated news and analysis of important M & A transactions. It’s the real deal!”

David Witkin - Beryl Capital Management

“The Capitol Forum has been an indispensable resource for me in analyzing regulatory risk affecting companies in my portfolio or watch list.”

RECENT ARTICLES | EDITOR'S PICKS

View all

RESOURCES

View all

Philip Mattera on Pay for Delay

Jun 01, 2023

This week on Second Request, the Hatch-Waxman Act of 1984 laid out a pathway for generic drugs to come to market as patent protections for brand name drugs expire. But brand-name producers have found...
Listen to Podcast
Thank you for subscribing to our newsletter